Celularity Inc: directors' dealings · United States · SEC (Form 4)

About Celularity Inc

Celularity Inc. is a biotechnology and regenerative medicine company listed on the Nasdaq in the United States under the ticker CELU. For investors, it is best understood as a speculative small-cap biotech whose value proposition is built around placental-derived biology. The company now positions itself as a longevity-focused cellular medicine platform, combining clinical-stage cell therapy development with a commercial biomaterials business derived from postpartum placenta. ([celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai)) The company’s roots trace back to Anthrogenesis, founded in 1998, followed by a merger with Celgene in 2002 and the spin-out that created Celularity in 2017. Celularity became a public company in 2021. Its current headquarters are in Florham Park, New Jersey, although older corporate materials also reference Warren, New Jersey during an earlier phase of facility development. ([celularity.com](https://celularity.com/about/?utm_source=openai)) Operationally, Celularity is built around two main business lines. First, it commercializes or monetizes placental biomaterials used in wound care and tissue repair applications. Second, it develops off-the-shelf, cryopreserved allogeneic cell therapies derived from the postpartum placenta, including natural killer (NK) cells, engineered T cells such as CAR-T constructs, and mesenchymal-like stromal cells. The company highlights an integrated manufacturing platform and a 150,000-square-foot facility dedicated to translational research and cellular medicine production. ([celularity.com](https://celularity.com/?utm_source=openai)) From a competitive standpoint, Celularity is trying to differentiate itself through a scalable manufacturing model and a ready-to-use product concept that avoids some of the logistical complexity of autologous cell therapies. That said, the company operates in a highly competitive and capital-intensive environment where success depends on clinical validation, manufacturing quality, regulatory execution, and financing discipline. Its development programs target oncology, infectious disease, degenerative disease, and biology of aging, which keeps the opportunity set broad but also scientifically demanding. ([celularity.com](https://celularity.com/?utm_source=openai)) Recent corporate developments suggest a deliberate strategic reset. In May 2026, Celularity announced that it had filed its Form 10-K and regained compliance with Nasdaq listing requirements after a delayed filing. The company also closed a transaction with NexGel that monetizes part of its biomaterials portfolio, entered a strategic license deal that could generate up to $35 million in upfront and milestone-related value, and received $12.2 million from the sale of unused New Jersey net operating losses and R&D tax credits. It additionally completed financing transactions to support ongoing operations and strategic initiatives. Taken together, these moves indicate a company focused on strengthening liquidity, sharpening its portfolio, and concentrating resources on its longevity-oriented therapeutic pipeline. ([celularity.com](https://celularity.com/celularity-announces-filing-of-form-10-k-regains-nasdaq-compliance-and-highlights-continued-strategic-transformation/?utm_source=openai))